The incidence of inflammatory bowel diseases (IBD) has rapidly increased over the last few years, as have increased their extraintestinal mannifestations and systemic complications. Renal manifestations of IBD, although rare, can lead to chronic renal failure and the need for renal replacement therapy with either dialysis or renal transplantation. Renal manifestations are primarily renal calculi, which have a tendency of appearing up to five times more frequently in IBD patients than in the general population, but also parenchymal diseases as IgA nephropathy, tubulointerstitial nephritis and secondary amyloidosis. Due to the nephrotoxicity of cyclosporine and possible development of acute tubulointerstitial nephritis as a consequence of mesalazin treatment, regular renal function monitoring is mandatory. New therapeutic options are being introduced for secondary and tertiary prevention of oxalate stones (probiotics featuring Oxalobacter formigenes) and glomerular IgA deposits (baminercept), with the intent of preserving renal homeostasis. Infliximab can prevent further renal deterioration in kidneys affected by amyloidosis. Furthermore, its use in patients on hemodialysis has been proven to be safe and necessary if rapid supression of intestinal inflammation is required. Patients with IBD having undegone renal transplantation tend to have better outcomes compared to liver transplant recipients. This is postulated to be the effect of more intensive imunosupressive therapy in kidney recipients.